Balyasny Asset Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-6,100
Closed -$1.67M 3486
2025
Q3
$1.67M Sell
6,100
-1,600
-21% -$437K ﹤0.01% 1888
2025
Q2
$1.99M Sell
7,700
-700
-8% -$167K ﹤0.01% 1733
2025
Q1
$1.88M Sell
8,400
-129,200
-94% -$30.2M ﹤0.01% 1733
2024
Q4
$31.5M Buy
137,600
+35,400
+35% +$8.52M 0.05% 478
2024
Q3
$24.9M Sell
102,200
-17,800
-15% -$3.98M 0.04% 553
2024
Q2
$23M Buy
120,000
+117,900
+5,614% +$23.9M 0.04% 558
2024
Q1
$416K Buy
+2,100
New +$385K ﹤0.01% 2121
2013
Q4
Sell
-35,000
Closed -$4.15M 609
2013
Q3
$4.15M Sell
35,000
-311,500
-90% -$15.1M 0.06% 375
2013
Q2
$15.6M Buy
+346,500
New +$16.4M 0.26% 94

Other funds holding RMD

Balyasny Asset Management's RMD Position: Q1 2026 in Review

Balyasny Asset Management reduced its ResMed (RMD) stake by 2% in Q1 2026, selling an estimated $11.2K and leaving 2,197 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #2371.

Balyasny Asset Management first reported a position in RMD in Q2 2015 and has held it in 24 quarters since. The position peaked at $65.8M in Q4 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Balyasny Asset Management held 2,197 shares of ResMed worth $493K as of Q1 2026.
  • Balyasny Asset Management sold 45 ResMed shares in Q1 2026, an estimated $11.2K.
  • ResMed made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2371 holding.
  • Balyasny Asset Management first reported a position in ResMed in Q2 2015 and has held it in 24 quarters since.
  • Balyasny Asset Management's ResMed position peaked at $65.8M in Q4 2021.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.